Highlights and Quick Summary
- Net Debt/EBITDA for the quarter ending February 28, 2023 was 18.79 (a -314.74% decrease compared to previous quarter)
- Year-over-year quarterly Net Debt/EBITDA decreased by -13.22%
- Annual Net Debt/EBITDA for 2022 was 5.07 (a 72.41% increase from previous year)
- Annual Net Debt/EBITDA for 2021 was 2.94 (a -926.13% decrease from previous year)
- Annual Net Debt/EBITDA for 2020 was -0.36 (a -413.02% decrease from previous year)
Visit stockrow.com/OGI
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Net Debt/EBITDA of Organigram Holdings Inc.
Most recent Net Debt/EBITDAof OGI including historical data for past 10 years.Interactive Chart of Net Debt/EBITDA of Organigram Holdings Inc.
Organigram Holdings Inc. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | 18.79 | – | – | – | – |
| 2022 | -8.75 | 60.61 | 21.65 | 50.31 | 5.07 |
| 2021 | 21.91 | 21.92 | 30.24 | 0.52 | 2.94 |
| 2020 | 0.81 | -1.01 | -0.43 | 146.05 | -0.36 |
| 2019 | 14.34 | -0.07 | 4.2 | -1621.0 | 0.11 |
| 2018 | – | – | 0.06 | -9.62 | -0.66 |
| 2017 | – | – | – | – | 3.72 |
| 2016 | – | – | – | – | -14.4 |
Business Profile of Organigram Holdings Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic